Lourd Capital’s AbbVie ABBV Stock Holding History

Lourd Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	$451K	Buy	6,200 +325	+6%	+$25.5K	0.04%	65
2019 Q1	$473K	Sell	5,875 -3,669	-38%	-$300K	0.05%	61
2018 Q4	$880K	Buy	9,544 +54	+0.6%	+$4.75K	0.07%	67
2018 Q3	$898K	Buy	+9,490	New	+$900K	0.06%	73
2018 Q1	–	Sell	-9,596	Closed	-$928K	–	121
2017 Q4	$928K	Buy	9,596 +3,328	+53%	+$314K	0.06%	77
2017 Q3	$557K	Buy	6,268 +13	+0.2%	+$990	0.05%	58
2017 Q2	$454K	Sell	6,255 -94	-1%	-$6.32K	0.04%	64
2017 Q1	$414K	Buy	6,349 +154	+2%	+$9.68K	0.04%	66
2016 Q4	$388K	Sell	6,195 -101	-2%	-$6.17K	0.04%	60
2016 Q3	$397K	Sell	6,296 -79	-1%	-$5.11K	0.04%	59
2016 Q2	$395K	Buy	6,375 +229	+4%	+$14K	0.11%	68
2016 Q1	$351K	Buy	6,146 +334	+6%	+$18.6K	0.04%	78
2015 Q4	$344K	Buy	5,812 +725	+14%	+$41.8K	0.04%	78
2015 Q3	$277K	Sell	5,087 -5	-0.1%	-$325	0.03%	86
2015 Q2	$342K	Buy	5,092 +120	+2%	+$7.83K	0.04%	83
2015 Q1	$291K	Buy	4,972 +96	+2%	+$5.8K	0.03%	100
2014 Q4	$319K	Sell	4,876 -2,333	-32%	-$147K	0.03%	86
2014 Q3	$416K	Sell	7,209 -1,488	-17%	-$82.6K	0.04%	65
2014 Q2	$491K	Buy	8,697 +1,797	+26%	+$94.3K	0.05%	62
2014 Q1	$355K	Sell	6,900 -600	-8%	-$30.3K	0.04%	68
2013 Q4	$396K	Hold	7,500	–	–	0.04%	64
2013 Q3	$335K	Hold	7,500	–	–	0.04%	70
2013 Q2	$310K	Buy	+7,500	New	+$328K	0.04%	77

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AAMU

Amundi Asset Management US Boston, Massachusetts $131B AUM 73.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Lourd Capital's ABBV Position: Q2 2019 in Review

Lourd Capital increased its AbbVie (ABBV) stake by 5.5% in Q2 2019, buying an estimated $25.5K and bringing the position to 6,200 shares worth $451K. The position accounts for 0.04% of the portfolio, ranked #65.

Lourd Capital first reported a position in ABBV in Q2 2013 and has held it in 23 quarters since. The position peaked at $928K in Q4 2017. 2,021 funds tracked by Wall St. Rank hold ABBV as of Q2 2019.

Lourd Capital held 6,200 shares of AbbVie worth $451K as of Q2 2019.
Lourd Capital bought 325 AbbVie shares in Q2 2019, an estimated $25.5K.
AbbVie made up 0.04% of Lourd Capital's portfolio in Q2 2019, its #65 holding.
Lourd Capital first reported a position in AbbVie in Q2 2013 and has held it in 23 quarters since.
Lourd Capital's AbbVie position peaked at $928K in Q4 2017.
2,021 funds tracked by Wall St. Rank held AbbVie as of Q2 2019.

Based on Lourd Capital's 13F filing for Q2 2019, filed 11 Jul 2019.